Institute Report No. 244

Genotoxic Potential of Reactive-Polymer in the
CHO HGPRT Forward Mutation Assay
and
CHO Sister Chromatid Exchange Assay

John W. Harbell, PhD, MAJ MSC
Lillie D. Witcher, BS, SGT USA
and
Don W. Korte, Jr., PhD, MAJ MSC

GENETIC AND CELLULAR TOXICOLOGY BRANCH
DIVISION OF TOXICOLOGY

LETTERMAN ARMY INSTITUTE OF RESEARCH
PRESIDIO OF SAN FRANCISCO, CALIFORNIA, 94129

This document has been approved for public release and sale to distribution is unlimited.
Genetic Potential of Reactive-Polymer in the CHO HGPRT Forward Mutation Assay and CHO Sister Chromatid Exchange Assay (Harbell, Witcher, and Korte)

Reproduction of this document in whole or in part is prohibited except with the permission of the Commander, Letterman Army Institute of Research, Presidio of San Francisco, California 94129. However, the Defense Technical Information Center is authorized to reproduce the document for United States Government purposes.

Destroy this report when it is no longer needed. Do not return to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense (AR 360-5)

Edwin S. Beattie
COL, MC
Commanding

This document has been approved for public release and sale its distribution is unlimited.
Genotoxic Potential of Reactive-Polymer in the CHO HGPRT Forward Mutation Assay and the CHO Sister Chromatid Exchange Assay

John W. Harbell, MAJ, MS, Lillie D. Witcher, SGt, USA, and Don W. Korte Jr., MAJ, MS

Final

August 1987

Reactive-polymer and its component parts were tested for their abilities to induce forward mutations in the CHO HGPRT Forward Mutation Assay and to damage DNA as measured by the CHO Sister Chromatid Exchange Assay. All materials were tested over dose ranges to include cytotoxic and noncytotoxic doses. Neither reactive-polymer nor its components induced a significant rise in the mutant frequency in the CHO HGPRT assay or in the frequency of sister chromatid exchanges. These data suggest a low genotoxic potential for reactive-polymer.
ABSTRACT

Reactive-polymer and its component parts were tested for their abilities to induce forward mutations in the CHO HGPRT Forward Mutation Assay and to damage DNA as measured by the CHO Sister Chromatid Exchange Assay. All materials were tested over dose ranges to include cytotoxic and noncytotoxic doses. Neither reactive-polymer nor its components induced a significant rise in the mutant frequency in the CHO HGPRT assay or in the frequency of sister chromatid exchanges. These data suggest a low genotoxic potential for reactive-polymer.

Key Words: Mutagenicity, Genetic Toxicology, HGPRT, Sister chromatid exchange, Chinese Hamster Ovary Cells, Reactive-polymer.
PREFACE

TYPE REPORT: Genetic Toxicology Study Report

TESTING FACILITY: Letterman Army Institute of Research
Presidio of San Francisco, CA 94129-6800

SPONSOR: US Army Medical Research and Development Command
Letterman Army Institute of Research
Presidio of San Francisco, CA 94129-6800

PROJECT/WORK UNIT/APC: Toxicity Testing of Antidotes for
Chemical Warfare Agents; Work Unit: 360; APC: TLEO

STUDY NUMBER: 74028

STUDY DIRECTOR: MAJ Don W. Korte Jr., PhD, MSC

PRINCIPAL INVESTIGATOR: MAJ John W. Harbell, PhD, MSC

TEST SUBSTANCE: Reactive-polymer (TP072)

INCLUSIVE STUDY DATES: 29 Oct 86 to 8 May 87

OBJECTIVE: The objective of this study was to determine the
genotoxic potential of reactive-polymer (TP072) by using the
CHO HGPRT Forward Mutation Assay and the CHO Sister Chromatid
Exchange Assay.
The authors wish to thank Sp4 Suzanne E. Sebastian for technical assistance.
SIGNATURES OF PRINCIPAL SCIENTISTS AND MANAGERS INVOLVED IN THE STUDY

We, the undersigned, declare that this study number 74028 was performed under our supervision, according to the procedures described herein, and that this report is an accurate record of the results obtained.

JOHN W. HARBELL, PhD / Date
MAJ, MS
Principal Investigator

LILLIE D. WITCHER B.S./ Date
SGT, USA
Co-Principal Investigator

DON W. KORTE, JR., PHD / Date
MAJ, MS
Study Director
TABLE OF CONTENTS

Abstract ........................................................................... 1
Preface ............................................................................ iii
Acknowledgments ............................................................. iv
Signatures of Principal Scientists ....................................... v
Table of Contents ........................................................... vi

BODY OF THE REPORT

INTRODUCTION
Objective of the Study ...................................................... 1

MATERIALS AND METHODS
Test Compound ................................................................. 1
Positive Control Chemicals ................................................. 1
Cells ................................................................................. 2
Assay Formats ..................................................................... 2

HGPRT Forward Mutation Assay ......................................... 2
CHO Sister Chromatid Exchange Assay ............................... 3

RESULTS ........................................................................... 4

DISCUSSION ..................................................................... 4

REFERENCES ..................................................................... 5

APPENDIX ......................................................................... 6

OFFICIAL DISTRIBUTION LIST .......................................... 8
The Genotoxic Potential of Reactive-polymer in the CHO HGPRT Forward Mutation Assay and the CHO Sister Chromatid Exchange Assay -- Harbell, Witcher, and Korte

Reactive-polymer is a potential reactive barrier against chemical agents. The Division of Toxicology, LAIR, was tasked by U.S. Army Natick Research, Development, and Engineering Center to assess the genotoxic potential of this material. Two distinct genotoxicity end points were chosen for this study: forward mutation and DNA damage. The first was assessed using the Chinese Hamster Ovary (CHO) hypoxanthine-guanine phosphoribosyl transferase (HGPRT) forward mutation assay (1) while the second was tested using the CHO sister chromatid exchange assay (2). These assays are normally conducted in this laboratory by following the Good Laboratory Practices (GLP) guidelines promulgated by the EPA. Due to the security classification of the material being tested, the assays for chemical composition and the independent audit required by these guidelines could not be employed. However, with the two exceptions listed above, the studies were conducted in accordance with GLP guidelines.

Objective of the Study

To examine the cytotoxicity, mutagenicity, and DNA-damaging capacity of reactive-polymer by using the CHO HGPRT forward mutation and CHO sister chromatid exchange assays.

MATERIALS AND METHODS

Test Compound

Reactive-polymer, its active components, and matrix components were evaluated in these assays. Reactive-polymer and its matrix were received as granules while the active components were a powder. The granules were ground to a fine powder by using a Spex liquid nitrogen mill (Spex Industries, Edison, New Jersey), sterilized in 70% ethanol for 20 minutes and then washed three times with sterile glass distilled water. All other materials were dissolved in sterile glass-distilled water and filter-sterilized. All dosing materials were prepared immediately before use.

Positive Control Chemicals

Ethyl methanesulfonate (EMS) (Sigma lot # 83F-0279) was dissolved in sterile glass-distilled water, filter-sterilized
through a 0.22 μm filter and added to the culture medium to achieve the desired final concentrations.

Cells

CHO cells subline CHO-K1-BH4 used for the HGPRT assay were obtained from Dr. A. Hsie, Oak Ridge National Laboratory, Oak Ridge, Tennessee. These cells were maintained in Ham's F12 (Irvine Scientific, Irvine, California) supplemented with 5% fetal bovine serum (FBS) (Hyclone Laboratories, Logan, Utah). Cell stocks were stored frozen in liquid nitrogen and an aliquot was thawed as needed for each assay. CHO cells used for the sister chromatid exchange assay were obtained from Dr. S. Wolff, University of California, San Francisco, San Francisco, California. These cells were grown in GEM 1717 (Irvine Scientific) supplemented with 10% FBS. No antibiotics were used in either culture system.

Assay Format:

HGPRT forward mutation assay

This assay has 4 stages: dosing, 24-hour cytotoxicity determination, 7-day mutation expression time, and finally quantitation of the mutant frequency in the cultures.

Dosing: Twenty cultures each containing 1.5 x 10^6 CHO HGPRT +/- cells in Ham's F12 with 5% FBS were exposed to the controls or test compounds for five hours, washed twice, and allowed to continue growing in Ham's F12 with 5% FBS to express whatever toxicity may have been induced by the treatment. Specific doses are given in Table I of the Appendix.

Cytotoxicity: After 24 hours, the cell monolayers were removed from the flasks with Ca** and Mg** free Hanks salt solution, and single cell suspensions were produced by gentle pipetting. Two hundred cells from each culture were plated into each of three dishes to determine the percentage of viable cells that remained after 24 hours. These plates were incubated for 7 days, fixed, stained with crystal violet, and the colonies counted. Data are expressed in terms of mean raw count (viable count), cloning efficiency (count/200), and percent of negative controls.

Mutation expression: From the remaining cells in each group, 1.5 x 10^6 cells were put into a fresh flask to continue growing. Since the cells have a doubling time of about 10-12 hours, it is necessary to split the cultures again on day 4 to prevent their overgrowth. Again single
cell suspensions were produced, and $1.5 \times 10^6$ cells were seeded into fresh flasks.

Quantitation of mutant frequency On day seven, by which time the mutant cells had lost all of their HGPRT enzyme, the populations were ready to undergo selective cloning to determine the relative number of mutant cells induced by each treatment. Both viable count cloning (as on day one) and selective cloning were performed. For the selective cloning of each treatment group, $2 \times 10^5$ cells were plated into each of 7 dishes which contained selection medium (total of $1.4 \times 10^6$ cells). Selection medium consisted of Ham's F12 without hypoxanthine but supplemented with 5% dialyzed FBS and $1.34 \times 10^{-5}$ M 6-thioguanine. 6-Thioguanine prevents cells that contain the HGPRT enzyme (nonmutants) from proliferating but does not harm the mutant cells. The viable count cloning was performed, as on day one, using selective medium without 6-thioguanine. After seven days, the plates were fixed, stained, and the colonies counted.

Data were expressed as mutants per million viable cells. For example, if the total number of mutant colonies on the seven selective cloning plates were 178 and the viable count were 134, then the mutant frequency would be:

$$178/(1.4 \times 10^6) \times (200/134) = 190.7 \text{ mutant clones per } 10^6 \text{ viable cells}$$

where

$1.4 \times 10^6 = 2 \times 10^5 \times 7$ was the total number of cells plated for the mutant count, and

$200/134$ was the inverse of the viable fraction and corrected for the percentage of dead cells in the cultures.

In order for a compound to be considered mutagenic it should induce a dose-correlated increase in mutant frequency with at least one dose yielding a threefold rise in the mutant frequency over controls. A single value in the middle of the dose range that produces a threefold increase without the correlated dose response relationship is generally not considered to signify an overall positive response.

**CHO sister chromatid exchange assay**

The CHO cells were grown and dosed in GEM 1717 supplemented with 10% fetal bovine serum. The sterilized test materials were dissolved directly in the medium. The dose groups and controls are given in Table II, in the Appendix. The cells were exposed for 24 hours to the compound and 5 uM 5-bromodeoxyuridine (BrdU). During the
last 2.5 hours of the growth period, colchicine (0.4 μg/ml final) was added to the medium to arrest mitoses. Cells were then harvested, swollen in hypotonic KCl, fixed, and chromosome spreads prepared. The chromosome preparations were stained using the method of Stetka and Wolf (3) to visualize the sister chromatid exchanges. Scoring was done on coded slides. One hundred cells in each treatment group were scored to determine the percentage of first, second, and third division metaphases. Normally 40 second-division metaphases, which contained all 20 chromosomes, were scored for sister chromatid exchanges (data listed as SCEs per metaphase). Data were analyzed by t-test between the negative and positive controls and ANOVA between the negative control and the test compound groups. The level of significance required for a positive response was p < 0.001.

RESULTS

The specific dosing materials, dose concentrations and the resulting mutation and SCE data are given in Tables I and II of the Appendix.

In the CHO HGPRT assay, compounds A and B showed marked toxicity at the highest doses tested (1.4-0.7 mg/ml and 4.0-2.0 mg/ml, respectively). Compound C was only moderately toxic even at the highest dose tested (4.0 mg/ml). As expected, the EMS induced a dose-dependent, statistically significant rise in the mutant frequency. Control frequency was 4.6 x 10^-6 while EMS at 0.075 and 0.15 mg/ml induced mutation frequencies of 190.7 x 10^-6 and 375.8 x 10^-6 respectively. Compound C induced greater than a threefold increase in the mutant frequency (18.3 x 10^-6) at 2.0 mg/ml, but this increase did not correlate with dose. No other significant increases in mutant frequency were observed.

In the CHO sister chromatid exchange assay, compound B was very toxic at doses above 2.0 mg/ml while the other compounds were only slightly toxic. Even at 2.0 mg/ml, cells treated with B showed 29% first division metaphases indicating a slowing of cell cycle times. EMS at 2.4 mg/flask (0.16 mg/ml) induced a statistically significant increase in the number of SCEs (control of 7.3 vs EMS of 13.3). None of the test compounds induced any significant increase in SCEs.

DISCUSSION

In the two assays employed, reactive-polymer and its components showed some cytotoxicity but did not induce significant increases in mutant frequency or SCEs. Both assays were considered valid in that the negative control values were within normal limits and the positive controls...
induced statistically significant responses. These data suggest a low genotoxic potential for reactive-polymer. Its cytotoxic action, however, might have an effect on very sensitive tissues (e.g. ocular), and therefore some care in handling this material would be appropriate.

REFERENCES


Appendix

Table 1

CHO HGPRT FORWARD MUTATION ASSAY
22 OCT 1986

<table>
<thead>
<tr>
<th>Compound Dose (mg/ml)</th>
<th>Viable Count (day one)</th>
<th>CEb</th>
<th>%C</th>
<th>Viable Count (day seven)</th>
<th>CE</th>
<th>%C</th>
<th>Mutant Frequency (x 10^-6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hg 0.0</td>
<td>171</td>
<td>86</td>
<td>100</td>
<td>174</td>
<td>87</td>
<td>100</td>
<td>4.6</td>
</tr>
<tr>
<td>EMS 0.075</td>
<td>134</td>
<td>67</td>
<td>78</td>
<td>133</td>
<td>67</td>
<td>76</td>
<td>190.7f</td>
</tr>
<tr>
<td>EMS 0.150</td>
<td>97</td>
<td>49</td>
<td>57</td>
<td>92</td>
<td>46</td>
<td>53</td>
<td>373.2f</td>
</tr>
<tr>
<td>A 1.40</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Too toxic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A 0.70</td>
<td>7</td>
<td>4</td>
<td>4</td>
<td>108</td>
<td>54</td>
<td>62</td>
<td>0.0f</td>
</tr>
<tr>
<td>A 0.52</td>
<td>111</td>
<td>56</td>
<td>65</td>
<td>152</td>
<td>76</td>
<td>87</td>
<td>7.5f</td>
</tr>
<tr>
<td>A 0.35</td>
<td>164</td>
<td>82</td>
<td>96</td>
<td>147</td>
<td>74</td>
<td>84</td>
<td>7.8f</td>
</tr>
<tr>
<td>A 0.26</td>
<td>179</td>
<td>90</td>
<td>105</td>
<td>144</td>
<td>72</td>
<td>83</td>
<td>11.3f</td>
</tr>
<tr>
<td>A 0.175</td>
<td>175</td>
<td>88</td>
<td>102</td>
<td>143</td>
<td>72</td>
<td>83</td>
<td>2.0f</td>
</tr>
<tr>
<td>B 4.0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Too toxic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B 2.0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>Too toxic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B 1.5</td>
<td>8</td>
<td>4</td>
<td>5</td>
<td>121</td>
<td>61</td>
<td>70</td>
<td>0.0f</td>
</tr>
<tr>
<td>B 1.0</td>
<td>86</td>
<td>43</td>
<td>50</td>
<td>157</td>
<td>79</td>
<td>90</td>
<td>5.4f</td>
</tr>
<tr>
<td>B 0.75</td>
<td>165</td>
<td>83</td>
<td>96</td>
<td>158</td>
<td>79</td>
<td>91</td>
<td>0.4f</td>
</tr>
<tr>
<td>B 0.5</td>
<td>176</td>
<td>88</td>
<td>103</td>
<td>168</td>
<td>84</td>
<td>97</td>
<td>3.4f</td>
</tr>
<tr>
<td>C 4.0</td>
<td>114</td>
<td>57</td>
<td>67</td>
<td>160</td>
<td>80</td>
<td>92</td>
<td>5.4f</td>
</tr>
<tr>
<td>C 2.0</td>
<td>135</td>
<td>67</td>
<td>79</td>
<td>164</td>
<td>82</td>
<td>94</td>
<td>18.3f</td>
</tr>
<tr>
<td>C 1.5</td>
<td>150</td>
<td>75</td>
<td>88</td>
<td>153</td>
<td>77</td>
<td>88</td>
<td>4.4f</td>
</tr>
<tr>
<td>C 1.0</td>
<td>136</td>
<td>68</td>
<td>80</td>
<td>158</td>
<td>79</td>
<td>91</td>
<td>5.4f</td>
</tr>
</tbody>
</table>

a Viable Count = number of colonies formed from 200 cells plated
b CE = Cloning Efficiency = viable count/200
c %C = percent of controls
d EMS = ethyl methanesulfonate
e Significant by the threefold-over-controls rule
f Not Significant
g Meets the threefold-over-controls rule however, no strong correlated dose response was achieved and therefore M was not considered to be significantly mutagenic.
A = Active  E = Reactive-polymer  C = Matrix
Table II
SISTER CHROMATID EXCHANGE ASSAY
1 Oct 86

<table>
<thead>
<tr>
<th>Compound</th>
<th>Dose</th>
<th>%FD</th>
<th>SCE</th>
<th>SD</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neg Cont.</td>
<td>2</td>
<td>7.1</td>
<td>3.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMS</td>
<td>2.4 mg/flask</td>
<td>2</td>
<td>13.3</td>
<td>4.3</td>
<td>p&lt;0.00001</td>
</tr>
<tr>
<td>A</td>
<td>0.75 mg/flask</td>
<td>15</td>
<td>8.0</td>
<td>3.7</td>
<td>NS</td>
</tr>
<tr>
<td>A</td>
<td>0.60 mg/flask</td>
<td>2</td>
<td>8.2</td>
<td>2.9</td>
<td>NS</td>
</tr>
<tr>
<td>A</td>
<td>0.45 mg/flask</td>
<td>15</td>
<td>7.6</td>
<td>2.8</td>
<td>NS</td>
</tr>
<tr>
<td>B</td>
<td>5.0 mg/flask</td>
<td>too toxic to score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>4.0 mg/flask</td>
<td>too toxic to score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>3.0 mg/flask</td>
<td>too toxic to score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>2.0 mg/flask</td>
<td>29</td>
<td>7.8</td>
<td>2.8</td>
<td>NS</td>
</tr>
<tr>
<td>B</td>
<td>1.0 mg/flask</td>
<td>12</td>
<td>8.4</td>
<td>2.8</td>
<td>NS</td>
</tr>
<tr>
<td>C</td>
<td>3.0 mg/flask</td>
<td>7</td>
<td>6.0</td>
<td>2.8</td>
<td>NS</td>
</tr>
<tr>
<td>C</td>
<td>2.0 mg/flask</td>
<td>6</td>
<td>7.5</td>
<td>2.6</td>
<td>NS</td>
</tr>
<tr>
<td>C</td>
<td>1.0 mg/flask</td>
<td>7</td>
<td>7.2</td>
<td>3.2</td>
<td>NS</td>
</tr>
<tr>
<td>Neg Cont.</td>
<td>6</td>
<td>7.4</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

%FD= percent in first division increase above controls indicates cytotoxicity and slowing of cell cycle.
SCE= sister chromatid exchanges
SD= standard deviation
NS= not significant

Control and treatment groups were compared using ANOVA at p < 0.001. Negative control and positive controls were compared using the t-test.
A= Active B= Reactive-polymer C= Matrix
OFFICIAL DISTRIBUTION LIST

Commander
US Army Medical Research
& Development Command
ATTN: SGRD-RMS/Mrs. Madigan
Fort Detrick, MD 21701-5012

Defense Technical Information Center
ATTN: DTIC/ADD (2 copies)
Cameron Station
Alexandria, VA 22304-6145

Office of Under Secretary of Defense
Research and Engineering
ATTN: R&T (E&LS), Room 3D129
The Pentagon
Washington, DC 20310-3080

The Surgeon General
ATTN: DASG-TLO
Washington, DC 20310

HQ DA (DASG-ZXA)
WASHINGTON DC 20310-2300

Commandant
Academy of Health Sciences
US Army
ATTN: IISHA-CDM
Fort Sam Houston, TX 78234-6100

Uniformed Services University of
Health Sciences
Office of Grants Management
4301 Jones Bridge Road
Baltimore, MD 20814-4799

US Army Research Office
ATTN: Chemical and Biological
Sciences Division
PO Box 12211
Research Triangle Park, NC 27709-2211

Director
ATTN: SGRD-UWZ-L
Walter Reed Army Institute of Research
Washington, DC, 20317-5100

Commander
US Army Medical Research Institute
of Infectious Diseases
ATTN: SGRD-ULZ-A
Fort Detrick, MD 21701-5011

Commander
US Army Medical Bioengineering Research
and Development Laboratory
ATTN: SGRD-UHG-M
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Medical Bioengineering Research
& Development Command
ATTN: Library
Fort Detrick, Bldg 568
Frederick, MD 21701-5010

Commander
US Army Research Institute of
Environmental Medicine
ATTN: SGRD-UH-RSA
Kansas Street
Natick, MA 01760-5007

Commander
US Army Research Institute of
Surgical Research
Fort Sam Houston, TX 78234-6200

Commander
US Army Aeromedical Research
Laboratory
Fort Rucker, AL 36362-5000

AIR FORCE Office of Scientific
Research (NS)
Building 410, Room A217
Bolling Air Force Base, DC 20332-6448

Commander
USAESAM/TSZ
Brooks Air Force Base, TX 78235-5000

Head, Biological Sciences Division
OFFICE OF NAVAL RESEARCH
800 North Quincy Street
Arlington, VA 22217-5000